Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Tamyo Mbisa, Public Health England

My name is Tamyo Mbisaand I am the head of the antiviral unit at Public Health England and with STOP-HCV, we are involved in the viral genomics structure so pretty much taking methods that have been developed within STOP-HCV on Hep C genome sequencing and trying to implement those in the clinical pathway.
At the moment, the project in PHE is really taking those methods, validating them and making them useful for implementation within clinical pathway.  The idea is to do that in the next year and launch the service within the NHS to support the delivery of drug of the new DAA’s and hopefully launch the service in 2018.  The idea is for whole genome sequencing to give you both Hep C genotyping as well as antiviral resistance in one single assay and at the moment we are using a different assays to do that so this will be an amalgamation of those services and give recommendations for that information at patient entry into clinical care.